[NAME OF THE MEDICINAL PRODUCT] Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Trimer Protein Vaccine (Sf9 Cell) 
[ADJUVANT] Squalene-based oil-in-water emulsion adjuvant
[THERAPEUTIC INDICATION] This vaccine is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 variants.

[STRENGTHS] Each vial contains 0.5 mL, with a total of 60 μg of recombinant S-RBD-HR trimeric protein (2 doses for human use). A single human dose is 0.25 mL containing 30 μg of recombinant S-RBD-HR trimeric protein.

On June 8, 2023, it was approved by the relevant national authorities for emergency use.